STAT3 and non-small cell lung carcinoma: Another ongoing phase II randomized study (NCT05689619) is ongoing in Italy, comparing silibinin (an oral STAT3 inhibitor) with a placebo in single brain metastasis from breast cancer and NSCLC following complete resection.